Bill Detail
S. 854
Congress: 119
Title
Risky Research Review Act
Summary
Risky Research Review Act This bill establishes the Life Sciences Research Security Board to oversee the award of federal funding for high-risk life sciences research. High-risk life sciences research means the study of an organism, virus, or related product that could be misapplied to pose a significant threat to the public or could enhance the transmissibility or virulence of certain high-risk pathogens (e.g., Ebola). Specifically, the bill establishes the board as an independent agency that must review proposed high-risk life sciences research, determine whether a federal agency may award funding for the research, and determine minimum required controls for funded research. Entities that are seeking federal funding must attest to whether their research is high-risk life sciences research. Agencies must certify the validity of these attestations and submit proposed high-risk life sciences research to the board. Agencies must also notify the board of intended awards for other life sciences research for potential review. In making its determinations, the board must consider specified factors, including whether the benefits of the research outweigh the risks. The bill prohibits agencies from awarding federal funding for high-risk life sciences research without approval of the board or for life sciences research currently under board review. The board may also review awards that were made before the bill’s enactment. Entities that fail to properly attest to the nature of their research may lose their eligibility for funding. Additionally, agency employees who fail to comply with the bill's requirements are subject to disciplinary action.
Sponsor
Sen. Rand Paul [R-KY]
Status
Placed on Senate Legislative Calendar under General Orders. Calendar No. 164.
Status as of Jun 29, 3:43 PM · synced 5h ago
Introduced
2025-03-05
Data source mode: cache
Bill Engagement
Risky Research Review Act This bill establishes the Life Sciences Research Security Board to oversee the award of federal funding for high-risk life sciences research.
Lobbyists on the case
- Association of American Medical Colleges4 filings · 4 lobs
- Biotechnology Innovation Organization1 filing · 13 lobs
- American Society for Microbiology1 filing · 3 lobs
- Devan O'toole2026 Q1
- Tannaz Rasouli2026 Q1
- Danielle Turnipseed2026 Q1
- Andrew Herrin2025 Q3
- Phyllis Arthur2025 Q1
- Amalia Corby-edwards2026 Q1
- Nicholas Cox2026 Q1
- Elisabeth Fox2025 Q1